Imatinib Grindeks (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, preventing phosphorylation of downstream signaling proteins. This inhibition blocks proliferative and survival signals in cancer cells, leading to reduced tumor growth and, in many patients, tumor regression.

The prescribed dose of Imatinib Grindeks is set by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Dosage adjustments are made according to clinical response and tolerability.

Safety data for Imatinib during pregnancy and lactation are limited. Animal studies suggest potential fetal risk, and the drug is excreted in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Imatinib Grindeks, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved for CML and remains a standard first‑line option. Second‑generation agents such as dasatinib and nilotinib have higher potency and may be chosen for patients with resistance or intolerance to imatinib, but they also carry distinct safety profiles.

Imatinib Grindeks should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Imatinib Grindeks is taken orally, usually once daily, with a glass of water. It can be swallowed with or without food; however, a consistent intake with respect to meals helps maintain stable drug levels. Patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations.

The most serious adverse events include severe neutropenia or leukopenia, which can predispose to infections; hepatotoxicity manifested by marked liver enzyme elevations or liver failure; and cardiac complications such as left‑ventricular dysfunction or heart failure. Prompt reporting of symptoms like fever, jaundice, or shortness of breath is essential.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the product. Those with severe hepatic impairment, uncontrolled cardiac disease, or a history of serious adverse reactions to tyrosine‑kinase inhibitors should be evaluated carefully, and alternative therapies may be preferred.